+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Diagnostics Market by Product Type, Test Type, End User, Technology, Application - Global Forecast to 2030- Product Image
Prostate Cancer Diagnostics Market by Product Type, Test Type, End User, Technology, Application - Global Forecast to 2030- Product Image
Sale

Prostate Cancer Diagnostics Market by Product Type, Test Type, End User, Technology, Application - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337436
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Prostate Cancer Diagnostics Market grew from USD 1.45 billion in 2024 to USD 1.67 billion in 2025. It is expected to continue growing at a CAGR of 14.24%, reaching USD 3.23 billion by 2030.

Introducing the Evolving Prostate Cancer Diagnostics Arena

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, presenting significant clinical and economic challenges. Early and accurate diagnosis has become paramount in improving patient outcomes, reducing treatment costs, and guiding personalized care pathways. Recent decades have witnessed a remarkable acceleration in diagnostic capabilities, driven by advances in molecular profiling, imaging resolution, and data analytics. These innovations are reshaping standard practice, enabling clinicians to detect disease at earlier stages and tailor interventions more precisely.

This executive summary offers a concise yet comprehensive overview of the current prostate cancer diagnostics environment. It highlights the transformative technological shifts that are redefining testing paradigms, the cumulative impact of new tariff policies in the United States, and critical market segmentation insights. Readers will gain clarity on regional growth drivers, competitive dynamics among leading industry players, and actionable recommendations designed to inform strategic decision-making. By synthesizing our rigorous research findings, this document equips healthcare professionals, investors, and industry leaders with the knowledge needed to navigate the evolving landscape of prostate cancer diagnostics.

Breakthrough Shifts Redefining Diagnostic Paradigms

The prostate cancer diagnostics landscape is undergoing a paradigm shift, driven by breakthroughs in imaging, biomolecular assays, and digital tools. High-resolution MRI and PET systems now offer unprecedented anatomical and functional insights, while molecular diagnostics have expanded to include liquid biopsies and next-generation sequencing panels that detect circulating tumor DNA and RNA markers. These emerging modalities, coupled with artificial intelligence-powered analytics, are transforming risk stratification, enabling clinicians to differentiate indolent from aggressive disease with greater confidence.

Concurrently, precision medicine initiatives are integrating genomic, proteomic, and radiomic data to develop highly individualized diagnostic protocols. This convergence accelerates time to diagnosis, reduces unnecessary invasive procedures, and supports adaptive treatment monitoring. As reimbursement frameworks evolve to acknowledge the value of early detection and personalized testing, healthcare systems are increasingly adopting these advanced solutions. The momentum behind these transformative shifts is unmistakable, setting the stage for a new era in which accuracy, speed, and patient-centricity define the future of prostate cancer diagnostics.

Tariff Impacts Reshaping US Supply Chains in 2025

The introduction of additional tariffs on imported diagnostic instruments, assay reagents, and biopsy consumables has created a ripple effect across the prostate cancer diagnostics ecosystem. Manufacturers of high-end imaging equipment, biopsy needles, and specialized molecular kits face increased input costs, prompting strategic reassessments of supply chain configurations. In response, several stakeholders are exploring regional manufacturing partnerships to localize assembly and reduce exposure to cross-border duties.

These tariff pressures have also influenced pricing negotiations with payers, driving a focus on cost-effective test panels and bundled service agreements. Laboratory providers are evaluating alternative reagent sources and investing in reagent-lite platforms to mitigate escalating costs. On the demand side, healthcare institutions are balancing the need for advanced diagnostics with budget constraints, prioritizing solutions that deliver clear clinical utility. Overall, the cumulative impact of 2025 tariff measures is fostering a more resilient, locally diversified supply network while accelerating innovation in cost-efficient testing approaches.

Deep Dive into Market Segmentation Nuances

A comprehensive understanding of market segmentation illuminates where growth opportunities and competitive pressures intersect. When viewed through the lens of product type, the diagnostics arena encompasses biomarkers and kits, biopsy needles, and imaging systems. Within biomarkers and kits, genetic testing, molecular assays, and PSA tests each serve distinct clinical needs, while imaging systems range from CT and MRI to PET and ultrasound modalities. This diversity of product offerings reflects the multifaceted demands of the diagnostic workflow.

Examining test types further refines this picture. Biopsy procedures continue to play a central role, yet imaging tests now span CT, MRI, PET, and ultrasound techniques, each selected based on patient risk profiles and institutional capabilities. Molecular tests, including next-generation sequencing and PCR assays, deliver deep insights into tumor biology and are increasingly integrated into diagnostic algorithms. PSA tests remain a staple for initial screening and monitoring, complementing more advanced approaches.

End-user segmentation highlights the roles of ambulatory surgical centers, diagnostic laboratories, hospitals and clinics, and research institutions in deploying diagnostic solutions. Technological segmentation reveals a balance between imaging modalities, immunoassays, and molecular diagnostics, each underpinned by specialized sub-technologies that drive performance. Finally, applications in genetic testing, initial diagnosis, and monitoring underscore the continuum of care addressed by these tools. This layered segmentation framework clarifies where investment, innovation, and collaboration will have the greatest strategic impact.

Regional Dynamics Steering Market Growth

Regional dynamics exert a powerful influence on technology adoption, regulatory pathways, and reimbursement frameworks. In the Americas, practitioners benefit from well-established screening programs and robust reimbursement policies, which support the uptake of advanced imaging systems and molecular assays. The region’s healthcare infrastructure fosters pilot deployments of AI-driven diagnostics and seamless integration of telepathology services.

Across Europe, the Middle East, and Africa, heterogeneity in healthcare funding models and regulatory harmonization presents both challenges and openings. Western European markets demonstrate strong demand for precision diagnostics, backed by public health initiatives, while emerging markets in Eastern Europe and the Middle East seek cost-effective solutions and capacity-building partnerships. Africa’s diagnostic landscape is characterized by infrastructure limitations but also by burgeoning interest in point-of-care molecular tests and mobile ultrasound units.

In the Asia-Pacific region, rapid investments in healthcare technology, expanding middle-class demographics, and evolving regulatory frameworks are driving significant momentum. Countries such as Japan and South Korea lead in imaging innovation, while China and India prioritize scalable, lower-cost assay kits to broaden access. Collaborative research networks and public-private partnerships further accelerate the region’s diagnostics development, positioning APAC as a key engine of global market growth.

Competitive Landscape and Leading Innovators

The competitive landscape is defined by a blend of multinational corporations, specialized diagnostics firms, and agile startups. Leading instrument manufacturers continue to invest heavily in research and development, enhancing imaging resolution and integrating AI algorithms that automate lesion detection and characterization. Meanwhile, biotechnology specialists focus on expanding molecular assay portfolios, optimizing panels for emerging biomarkers, and streamlining laboratory workflows.

Strategic collaborations between device companies and digital health providers are generating comprehensive diagnostic ecosystems that span data capture, analysis, and clinical reporting. Concurrently, consolidation through mergers and acquisitions is reshaping market share dynamics, as larger firms acquire niche innovators to broaden their technology offerings. Companies that demonstrate deep domain expertise in prostate cancer-specific diagnostics and maintain flexible regulatory strategies have secured early traction in key geographies.

Emerging players are differentiating themselves by leveraging novel chemistries, machine learning frameworks, and point-of-care platforms designed for decentralized testing. These innovative entrants are compelling incumbents to accelerate their own innovation roadmaps, ensuring a vibrant and competitive environment that ultimately benefits patients and healthcare systems.

Strategic Imperatives for Industry Leadership

Industry leaders must adopt a multifaceted strategy to capitalize on evolving diagnostic opportunities. First, forging partnerships with academic research centers and technology incubators will expedite the translation of novel biomarkers and imaging algorithms into validated clinical tools. Engaging early with regulatory agencies to align on trial designs and submission pathways will reduce approval timelines and facilitate market entry.

Second, investing in flexible manufacturing and supply chain models will mitigate tariff risks and ensure continuity of reagent and instrument availability. Establishing regional production hubs for kits and consumables can unlock cost efficiencies and strengthen collaboration with local distributors. Third, integrating digital health capabilities-such as cloud-based data platforms and AI-enabled decision support-will enhance product value and create sticky relationships with end users.

Finally, prioritizing patient centricity by developing user-friendly interfaces, educational resources, and coordinated care pathways will drive adoption and improve clinical outcomes. By embracing these strategic imperatives, diagnostics companies can differentiate their offerings, navigate complex market dynamics, and deliver sustainable growth.

Rigorous Research Framework Guiding Insights

Our research methodology combines rigorous primary and secondary approaches to produce a robust, validated data set. Extensive secondary research draws on peer-reviewed journals, regulatory filings, patent databases, and corporate disclosures to map technological developments, competitive activities, and policy environments. Supplementing this foundation, primary interviews with key opinion leaders, laboratory directors, payers, and procurement specialists provide firsthand perspectives on clinical adoption drivers and operational challenges.

Quantitative data analysis leverages proprietary and public databases to track sales volumes, instrument installations, and test volumes across major diagnostic categories. Qualitative insights from expert panels inform interpretation of emerging trends and regional dynamics. Data triangulation techniques reconcile discrepancies between sources, ensuring accuracy and completeness.

All findings undergo systematic validation through cross-referencing with industry benchmarks and consultation with external advisory boards. This mixed-methods framework delivers a nuanced, high-confidence view of the prostate cancer diagnostics market, enabling stakeholders to make informed strategic decisions.

Summarizing the Path Forward

The prostate cancer diagnostics market stands at a pivotal juncture, characterized by rapid technological innovation, shifting trade policies, and an increasingly segmented landscape. The integration of advanced imaging systems with molecular diagnostics and AI analytics is elevating diagnostic precision and enabling truly personalized patient pathways. Meanwhile, tariff adjustments in the United States have underscored the importance of supply chain resilience and regional manufacturing capabilities.

Segmentation analysis reveals targeted opportunities across product types, test modalities, end users, and application areas, while regional insights highlight the distinct drivers and barriers in the Americas, EMEA, and Asia-Pacific. Competitive dynamics reflect both consolidation among established players and the disruptive potential of nimble startups. To thrive in this environment, industry participants must adopt proactive strategies encompassing strategic partnerships, digital integration, and patient-centric innovation.

Equipped with these comprehensive insights, decision-makers can confidently navigate the complexities of the prostate cancer diagnostics market, capitalize on emerging trends, and shape a future defined by early detection, precision care, and sustained growth.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product Type
    • Biomarkers & Kits
      • Genetic Testing Kits
      • Molecular Diagnostic Kits
      • Psa Tests
    • Biopsy Needles
    • Imaging Systems
      • Ct Systems
      • Mri Systems
      • Pet Systems
      • Ultrasound Systems
  • Test Type
    • Biopsy
    • Imaging Tests
      • Ct Tests
      • Mri Tests
      • Pet Tests
      • Ultrasound Tests
    • Molecular Tests
      • Ngs Tests
      • Pcr Tests
    • Psa Test
  • End User
    • Ambulatory Surgical Centers
    • Diagnostic Centers
    • Hospitals & Clinics
    • Research Laboratories
  • Technology
    • Imaging Modalities
      • Ct Modalities
      • Mri Modalities
      • Pet Modalities
      • Ultrasound Modalities
    • Immunoassays
      • Elisa
      • Ria
    • Molecular Diagnostics
      • Ngs Technologies
      • Pcr Technologies
  • Application
    • Genetic Testing
    • Initial Diagnosis
    • Monitoring & Follow-Up
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Hologic, Inc.
  • bioMérieux SA
  • QIAGEN N.V.
  • Laboratory Corporation of America Holdings
  • Illumina, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Prostate Cancer Diagnostics Market, by Product Type
8.1. Introduction
8.2. Biomarkers & Kits
8.2.1. Genetic Testing Kits
8.2.2. Molecular Diagnostic Kits
8.2.3. Psa Tests
8.3. Biopsy Needles
8.4. Imaging Systems
8.4.1. Ct Systems
8.4.2. Mri Systems
8.4.3. Pet Systems
8.4.4. Ultrasound Systems
9. Prostate Cancer Diagnostics Market, by Test Type
9.1. Introduction
9.2. Biopsy
9.3. Imaging Tests
9.3.1. Ct Tests
9.3.2. Mri Tests
9.3.3. Pet Tests
9.3.4. Ultrasound Tests
9.4. Molecular Tests
9.4.1. Ngs Tests
9.4.2. Pcr Tests
9.5. Psa Test
10. Prostate Cancer Diagnostics Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Diagnostic Centers
10.4. Hospitals & Clinics
10.5. Research Laboratories
11. Prostate Cancer Diagnostics Market, by Technology
11.1. Introduction
11.2. Imaging Modalities
11.2.1. Ct Modalities
11.2.2. Mri Modalities
11.2.3. Pet Modalities
11.2.4. Ultrasound Modalities
11.3. Immunoassays
11.3.1. Elisa
11.3.2. Ria
11.4. Molecular Diagnostics
11.4.1. Ngs Technologies
11.4.2. Pcr Technologies
12. Prostate Cancer Diagnostics Market, by Application
12.1. Introduction
12.2. Genetic Testing
12.3. Initial Diagnosis
12.4. Monitoring & Follow-Up
13. Americas Prostate Cancer Diagnostics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Prostate Cancer Diagnostics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Prostate Cancer Diagnostics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Roche Diagnostics International AG
16.3.2. Abbott Laboratories
16.3.3. Danaher Corporation
16.3.4. Thermo Fisher Scientific Inc.
16.3.5. Siemens Healthineers AG
16.3.6. Hologic, Inc.
16.3.7. bioMérieux SA
16.3.8. QIAGEN N.V.
16.3.9. Laboratory Corporation of America Holdings
16.3.10. Illumina, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. PROSTATE CANCER DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. PROSTATE CANCER DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTIC KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY NEEDLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PSA TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CT MODALITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MRI MODALITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PET MODALITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND MODALITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY RIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY NGS TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCR TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INITIAL DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MONITORING & FOLLOW-UP, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 84. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 85. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 86. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 87. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 88. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 90. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 91. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 92. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 93. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 96. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 97. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 98. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 101. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 103. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 157. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 159. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 160. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 161. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 164. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 165. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 166. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 169. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 170. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 172. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 173. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 175. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 176. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 178. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 192. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 193. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 194. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 195. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 196. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 197. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 200. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 201. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 202. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 205. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 206. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 207. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 208. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 209. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 212. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 214. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 253. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 254. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 255. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 256. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 257. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 259. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 260. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 261. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 262. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 276. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 277. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 278. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 279. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 280. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 281. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 282. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 283. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 284. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 285. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 286. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 289. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 290. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 291. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 292. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 293. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 296. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 297. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 298. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 302. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 303. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
TABLE 304. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2030 (USD MILLION)
TABLE 305. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 307. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING MODALITIES, 2018-2030 (USD MILLION)
TABLE 308. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
TABLE 309. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 310. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 311. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2030 (USD MILLIO

Companies Mentioned

The companies profiled in this Prostate Cancer Diagnostics market report include:
  • Roche Diagnostics International AG
  • Abbott Laboratories
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Siemens Healthineers AG
  • Hologic, Inc.
  • bioMérieux SA
  • QIAGEN N.V.
  • Laboratory Corporation of America Holdings
  • Illumina, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.67 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.23 Billion
Compound Annual Growth Rate14.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Prostate Cancer Diagnostics - Global Strategic Business Report - Product Image

Prostate Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F - Product Image

Prostate Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Prostate Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Prostate Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Prostate Cancer Diagnostics Market Report 2025 - Product Image

Prostate Cancer Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Prostate Cancer Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Prostate Cancer Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From

About the Prostate Cancer Diagnostics Market

The Prostate Cancer Diagnostics market is a segment of the Diagnostics industry that focuses on the detection and diagnosis of prostate cancer. Diagnostic tests for prostate cancer include digital rectal exams, prostate-specific antigen (PSA) tests, and biopsies. These tests are used to detect the presence of cancer, as well as to monitor the progression of the disease. In recent years, advances in technology have enabled the development of more accurate and reliable diagnostic tests for prostate cancer. These tests have improved the accuracy of diagnosis and have enabled earlier detection of the disease. Additionally, the development of new treatments for prostate cancer has increased the demand for diagnostic tests. The Prostate Cancer Diagnostics market is highly competitive, with a number of companies offering a range of diagnostic tests. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Siemens Healthineers, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.